Home>Topics>Stocks>Valeant Pharmaceuticals International

Valeant Pharmaceuticals International VRX

  1. All
  2. Commentary
  3. Headlines
    1. Valeant to focus on smaller, private deals in 2015 -CEO

      Headlines

      Thu, 8 Jan 2015

      Jan 8 (Reuters) - Valeant Pharmaceuticals International Inc will focus its acquisition strategy on smaller, private companies in 2015, Chief Executive Michael Pearson said on Thursday.

    2. Valeant raises 2015 adjusted profit outlook more than expected

      Headlines

      Thu, 8 Jan 2015

      Jan 8 (Reuters) - Valeant Pharmaceuticals International Inc said on Thursday that it expected in 2015 to reap revenue of $9.2 billion to $9.3 billion and cash earnings of $10.10 to $10.40 per share, exceeding last year's results.

    3. 2014's Biggest Stock Winners: Is There Any Gas Left in the Tank?

      Headlines

      Wed, 7 Jan 2015

      shares nearly doubled in value in 2014, as the maker of Botox was initially pursued by hostile suitor Valeant Pharmaceuticals VRX and eventually Actavis. In November 2014, Actavis announced it would be acquiring Allergan at $219 per share, in a $66 billion

    4. Nominees for 2014 Domestic-Stock Fund Manager of the Year

      Headlines

      Mon, 5 Jan 2015

      the company's pipeline. These were the same qualities that attracted bids from would-be acquisitor Valeant Pharmaceuticals VRX and eventual merger partner Actavis ACT. The fund tends to cluster in some sectors and ignore others, so it can look out of

    5. From Barron’s, January 5, 2015 (Part 1)

      Commentary

      Sat, 3 Jan 2015

      is attractive for a rebound play. Strong large-cap performers with significant insider activity include KMI, REGN, RSG, VRX , CHTR, DVA, TWX . For the week , DJIA -1.22% , SP500 -1.46% , Nasdaq Comp -1.67% , Russell 2000 -1.35% . DJ

    6. Health Care: A Strong Run, but Some Stocks Still Look Undervalued

      Headlines

      Wed, 31 Dec 2014

      failed attempt earlier in the year. However, the white knight acquisition of Allergan AGN by Actavis ACT to fend off Valeant VRX looks likely to complete and showcases the importance of scale and cost-cutting between two major health-care companies

    7. Ultimate Stock-Pickers: Top Holdings of Top-Performing Managers

      Headlines

      Tue, 16 Dec 2014

      benchmark index). Allergan AGN "> AGN , which has been the subject of a takeover battle, with Valeant Pharmaceuticals VRX "> VRX on one side with a $180 per share bid and Actavis ACT "> ACT on the other side with a $219 per share offer, has been

    8. For David Krempa - VRX

      Commentary

      Mon, 1 Dec 2014

      Do you expect to prepare an analyst note anytime soon on Valeant’s prospects following the abortive Allergan deal?

    9. From Barron’s, November 10, 2014 (Part 2)

      Commentary

      Sat, 8 Nov 2014

      US techs such as AMZN Ackman/Pershing Square Capital: started rumors about railroad consolidation; himself involved with VRX , CP Pg 29: An interview with 4 experts [ Weber -Morgan Stanley, Oberlander -Merrill Lynch, Pell-Ameriprise, Brede -own

    10. UPDATE 3-Valeant says ready to raise Allergan bid to at least $200/share

      Headlines

      Mon, 27 Oct 2014

      Oct 27 (Reuters) - Valeant Pharmaceuticals International Inc on Monday said in a letter to Allergan Inc's board of directors that it was prepared to raise its offer to at least $200 per share but...

    « Prev12345Next »
    Content Partners